The Department for Health and Social Care has asked NICE to conduct an appraisal of anifrolumab for treating active autoantibody-positive systemic lupus erythematosus.
Please note that following on from a request from the company, the timelines for this appraisal have been revised to facilitate a suitably comprehensive submission. The invitation to participate is now scheduled to be sent out in early June 2021 with submissions due in early August 2021.
As this appraisal has been referred, NICE will continue to monitor any developments and will provide an update as and when the situation changes.